Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human/Mouse/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-CDKN1C/p57 Kip2 (1-107) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.05% Proclin300, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:1000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
CDKN1C |
Gene ID: |
1028 |
Uniprot ID: |
CDN1C_HUMAN |
Immunogen Region: |
1-107 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 1-107 of human CDKN1C/p57 Kip2 (NP_000067.1). |
Immunogen Sequence: |
MSDASLRSTSTMERLVARGT FPVLVRTSACRSLFGPVDHE ELSRELQARLAELNAEDQNR WDYDFQQDMPLRGPGRLQWT EVDSDSVPAFYRETVQVGRC RLLLAPR |
Tissue Specificity | Expressed in the heart, brain, lung, skeletal muscle, kidney, pancreas and testis. Expressed in the eye. High levels are seen in the placenta while low levels are seen in the liver. |
Function | Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non-proliferative state throughout life. |
Protein Name | Cyclin-Dependent Kinase Inhibitor 1cCyclin-Dependent Kinase Inhibitor P57P57kip2 |
Database Links | Reactome: R-HSA-69231Reactome: R-HSA-9661069 |
Cellular Localisation | Nucleus |
Alternative Antibody Names | Anti-Cyclin-Dependent Kinase Inhibitor 1c antibodyAnti-Cyclin-Dependent Kinase Inhibitor P57 antibodyAnti-P57kip2 antibodyAnti-CDKN1C antibodyAnti-KIP2 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance